# Health Catalyst, Inc.: financial statements, quarterly

HCAT · Nasdaq · CIK 1636422 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hcat.md) · [Financials](/companies/hcat/financials.md) · [Filings](/companies/hcat/filings.md) · [Insiders](/companies/hcat/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hcat/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [73.8](/filings/0001636422-24-000152.md) | [75.1 d](/filings/0001636422-26-000035.md) | [74.7](/filings/0001636422-25-000069.md) | [75.9](/filings/0001636422-25-000111.md) | [76.4](/filings/0001636422-25-000146.md) | [79.6 d](/filings/0001636422-26-000035.md) | [79.4](/filings/0001636422-26-000066.md) | [80.7](/filings/0001636422-26-000097.md) | [76.3](/filings/0001636422-25-000146.md) | [74.7 d](/filings/0001636422-26-000035.md) | [70.8](/filings/0001636422-26-000066.md) | [70.5](/filings/0001636422-26-000097.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | [36.3](/filings/0001636422-25-000146.md) | not reported | not reported | not reported | [40.1](/filings/0001636422-25-000146.md) | not reported | not reported | not reported |
| Research and development | $m | [17.7](/filings/0001636422-24-000152.md) | [20.3 d](/filings/0001636422-26-000035.md) | [14.9](/filings/0001636422-25-000069.md) | [13.9](/filings/0001636422-25-000111.md) | [14.2](/filings/0001636422-25-000146.md) | [15.0 d](/filings/0001636422-26-000035.md) | [15.2](/filings/0001636422-26-000066.md) | [12.4](/filings/0001636422-26-000097.md) | [12.3](/filings/0001636422-25-000146.md) | [9.9 d](/filings/0001636422-26-000035.md) | [9.8](/filings/0001636422-26-000066.md) | [11.0](/filings/0001636422-26-000097.md) |
| Operating income | $m | [(24.6)](/filings/0001636422-24-000152.md) | [(32.8) d](/filings/0001636422-26-000035.md) | [(22.8)](/filings/0001636422-25-000069.md) | [(15.8)](/filings/0001636422-25-000111.md) | [(13.7)](/filings/0001636422-25-000146.md) | [(17.5) d](/filings/0001636422-26-000035.md) | [(20.2)](/filings/0001636422-26-000066.md) | [(37.1)](/filings/0001636422-26-000097.md) | [(17.5)](/filings/0001636422-25-000146.md) | [(86.1) d](/filings/0001636422-26-000035.md) | [(106)](/filings/0001636422-26-000066.md) | [(36.5)](/filings/0001636422-26-000097.md) |
| Income tax | $m | [0.1](/filings/0001636422-24-000152.md) | [0.1 d](/filings/0001636422-26-000035.md) | [0.1](/filings/0001636422-25-000069.md) | [0.1](/filings/0001636422-25-000111.md) | [(0.5)](/filings/0001636422-25-000146.md) | [0.6 d](/filings/0001636422-26-000035.md) | [0.2](/filings/0001636422-26-000066.md) | [0.1](/filings/0001636422-26-000097.md) | [0.0](/filings/0001636422-25-000146.md) | [0.4 d](/filings/0001636422-26-000035.md) | [0.4](/filings/0001636422-26-000066.md) | [0.3](/filings/0001636422-26-000097.md) |
| Net income | $m | [(22.0)](/filings/0001636422-24-000152.md) | [(30.3) d](/filings/0001636422-26-000035.md) | [(20.6)](/filings/0001636422-25-000069.md) | [(13.5)](/filings/0001636422-25-000111.md) | [(14.7)](/filings/0001636422-25-000146.md) | [(20.7) d](/filings/0001636422-26-000035.md) | [(23.7)](/filings/0001636422-26-000066.md) | [(41.0)](/filings/0001636422-26-000097.md) | [(22.2)](/filings/0001636422-25-000146.md) | [(91.0) d](/filings/0001636422-26-000035.md) | [(111)](/filings/0001636422-26-000066.md) | [(40.5)](/filings/0001636422-26-000097.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0001636422-24-000152.md) | not reported | [(0.35)](/filings/0001636422-25-000069.md) | [(0.23)](/filings/0001636422-25-000111.md) | [(0.24)](/filings/0001636422-25-000146.md) | not reported | [(0.35)](/filings/0001636422-26-000066.md) | [(0.59)](/filings/0001636422-26-000097.md) | [(0.32)](/filings/0001636422-25-000146.md) | not reported | [(1.53)](/filings/0001636422-26-000066.md) | [(0.55)](/filings/0001636422-26-000097.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0001636422-24-000152.md) | not reported | [(0.35)](/filings/0001636422-25-000069.md) | [(0.23)](/filings/0001636422-25-000111.md) | [(0.24)](/filings/0001636422-25-000146.md) | not reported | [(0.35)](/filings/0001636422-26-000066.md) | [(0.59)](/filings/0001636422-26-000097.md) | [(0.32)](/filings/0001636422-25-000146.md) | not reported | [(1.53)](/filings/0001636422-26-000066.md) | [(0.55)](/filings/0001636422-26-000097.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [95.0](/filings/0001636422-23-000133.md) | [106](/filings/0001636422-25-000028.md) | [201](/filings/0001636422-24-000075.md) | [202](/filings/0001636422-24-000120.md) | [328](/filings/0001636422-24-000152.md) | [250](/filings/0001636422-26-000035.md) | [342](/filings/0001636422-25-000069.md) | [50.7](/filings/0001636422-25-000111.md) | [40.3](/filings/0001636422-25-000146.md) | [50.8](/filings/0001636422-26-000097.md) | [59.9](/filings/0001636422-26-000066.md) | [60.6](/filings/0001636422-26-000097.md) |
| Current assets | $m | [408](/filings/0001636422-23-000133.md) | [393](/filings/0001636422-25-000028.md) | [397](/filings/0001636422-24-000075.md) | [376](/filings/0001636422-24-000120.md) | [457](/filings/0001636422-24-000152.md) | [466](/filings/0001636422-26-000035.md) | [423](/filings/0001636422-25-000069.md) | [181](/filings/0001636422-25-000111.md) | [165](/filings/0001636422-25-000146.md) | [169](/filings/0001636422-26-000097.md) | [182](/filings/0001636422-26-000066.md) | [248](/filings/0001636422-26-000097.md) |
| Total assets | $m | [713](/filings/0001636422-23-000133.md) | [702](/filings/0001636422-25-000028.md) | [695](/filings/0001636422-24-000075.md) | [692](/filings/0001636422-24-000120.md) | [813](/filings/0001636422-24-000152.md) | [859](/filings/0001636422-26-000035.md) | [892](/filings/0001636422-25-000069.md) | [616](/filings/0001636422-25-000111.md) | [587](/filings/0001636422-25-000146.md) | [503](/filings/0001636422-26-000097.md) | [412](/filings/0001636422-26-000066.md) | [359](/filings/0001636422-26-000097.md) |
| Current liabilities | $m | [84.3](/filings/0001636422-23-000133.md) | [89.0](/filings/0001636422-25-000028.md) | [92.2](/filings/0001636422-24-000075.md) | [318](/filings/0001636422-24-000120.md) | [324](/filings/0001636422-24-000152.md) | [326](/filings/0001636422-26-000035.md) | [340](/filings/0001636422-25-000069.md) | [98.8](/filings/0001636422-25-000111.md) | [87.9](/filings/0001636422-25-000146.md) | [89.6](/filings/0001636422-26-000097.md) | [108](/filings/0001636422-26-000066.md) | [91.9](/filings/0001636422-26-000097.md) |
| Total liabilities | $m | [331](/filings/0001636422-23-000133.md) | [335](/filings/0001636422-25-000028.md) | [338](/filings/0001636422-24-000075.md) | [335](/filings/0001636422-24-000120.md) | [458](/filings/0001636422-24-000152.md) | [494](/filings/0001636422-26-000035.md) | [515](/filings/0001636422-25-000069.md) | [269](/filings/0001636422-25-000111.md) | [255](/filings/0001636422-25-000146.md) | [257](/filings/0001636422-26-000097.md) | [274](/filings/0001636422-26-000066.md) | [258](/filings/0001636422-26-000097.md) |
| Long-term debt | $m | [228](/filings/0001636422-23-000133.md) | [228](/filings/0001636422-25-000028.md) | [228](/filings/0001636422-24-000075.md) | [0.0](/filings/0001636422-24-000120.md) | [115](/filings/0001636422-24-000152.md) | [151](/filings/0001636422-26-000035.md) | [151](/filings/0001636422-25-000069.md) | [151](/filings/0001636422-25-000111.md) | [152](/filings/0001636422-25-000146.md) | [152](/filings/0001636422-26-000097.md) | [152](/filings/0001636422-26-000066.md) | [152](/filings/0001636422-26-000097.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001636422-25-000028.md) | not reported | not reported | [230](/filings/0001636422-24-000152.md) | [231](/filings/0001636422-26-000035.md) | [232](/filings/0001636422-25-000069.md) | [1.6](/filings/0001636422-25-000111.md) | [1.6](/filings/0001636422-25-000146.md) | [1.6](/filings/0001636422-26-000097.md) | [1.6](/filings/0001636422-26-000066.md) | [1.6](/filings/0001636422-26-000097.md) |
| Shareholders' equity | $m | [382](/filings/0001636422-24-000152.md) | [367](/filings/0001636422-26-000035.md) | [357](/filings/0001636422-25-000111.md) | [357](/filings/0001636422-25-000146.md) | [355](/filings/0001636422-25-000146.md) | [365](/filings/0001636422-26-000097.md) | [377](/filings/0001636422-26-000097.md) | [348](/filings/0001636422-26-000097.md) | [332](/filings/0001636422-25-000146.md) | [246](/filings/0001636422-26-000097.md) | [138](/filings/0001636422-26-000097.md) | [101](/filings/0001636422-26-000097.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3.1 d](/filings/0001636422-24-000152.md) | [(19.0) d](/filings/0001636422-26-000035.md) | [10.3](/filings/0001636422-25-000069.md) | [1.6 d](/filings/0001636422-25-000111.md) | [6.2 d](/filings/0001636422-25-000146.md) | [(3.5) d](/filings/0001636422-26-000035.md) | [0.3](/filings/0001636422-26-000066.md) | [(9.0) d](/filings/0001636422-26-000097.md) | [(0.5) d](/filings/0001636422-25-000146.md) | [9.9 d](/filings/0001636422-26-000035.md) | [18.5](/filings/0001636422-26-000066.md) | [0.3 d](/filings/0001636422-26-000097.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001636422-24-000152.md) | [0.3 d](/filings/0001636422-26-000035.md) | [0.2](/filings/0001636422-25-000069.md) | [0.3 d](/filings/0001636422-25-000111.md) | [0.7 d](/filings/0001636422-25-000146.md) | [0.4 d](/filings/0001636422-26-000035.md) | [0.7](/filings/0001636422-26-000066.md) | [(0.2) d](/filings/0001636422-26-000097.md) | [0.3 d](/filings/0001636422-25-000146.md) | [0.3 d](/filings/0001636422-26-000035.md) | [0.3](/filings/0001636422-26-000066.md) | [0.3 d](/filings/0001636422-26-000097.md) |
| Share repurchases | $m | [0.0 d](/filings/0001636422-24-000152.md) | [0.0 d](/filings/0001636422-26-000035.md) | [0.0](/filings/0001636422-25-000069.md) | [0.0 d](/filings/0001636422-25-000111.md) | [0.0 d](/filings/0001636422-25-000146.md) | [0.0 d](/filings/0001636422-26-000035.md) | [5.0](/filings/0001636422-26-000066.md) | [0.0 d](/filings/0001636422-26-000097.md) | [0.0 d](/filings/0001636422-25-000146.md) | [0.0 d](/filings/0001636422-26-000035.md) | [0.0](/filings/0001636422-26-000066.md) | [0.0 d](/filings/0001636422-26-000097.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.3](/filings/0001636422-23-000133.md) | [55.5](/filings/0001636422-24-000075.md) | [56.0](/filings/0001636422-24-000120.md) | [56.7](/filings/0001636422-24-000152.md) | [58.6](/filings/0001636422-25-000069.md) | [59.3](/filings/0001636422-25-000111.md) | [60.4](/filings/0001636422-25-000146.md) | [68.6](/filings/0001636422-26-000066.md) | [69.6](/filings/0001636422-26-000097.md) | [70.4](/filings/0001636422-25-000146.md) | [72.6](/filings/0001636422-26-000066.md) | [74.0](/filings/0001636422-26-000097.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 75,256,381 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001636422-26-000097.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.